Top

Published in:

01-09-2015 | Research

Thrombocytosis of Liver Metastasis from Colorectal Cancer as Predictive Factor

Authors: Valéria Jósa, Marcin Krzystanek, Tamás Vass, Tamás Lang, Viktória Juhász, Kamilla Szilágyi, Balázs Tihanyi, László Harsányi, Zoltán Szállási, Ferenc Salamon, Zsolt Baranyai

Published in: Pathology & Oncology Research | Issue 4/2015

Abstract

There is increasing evidence that thrombocytosis is associated with tumor invasion and metastasis formation. It was shown in several solid tumor types that thrombocytosis prognosticates cancer progression. The aim of this study was to evaluate preoperative thrombocytosis as a potential prognostic biomarker in isolated metastases, in patients with liver metastasis of colorectal cancer (mCRC). Clinicopathological data of 166 patients with mCRC who had surgical resection between 2001 and 2011 were collected retrospectively. All primary tumors have been already resected. The platelet count was evaluated based on the standard preoperative blood profile. The patients were followed-up on average for 28 months. Overall survival (OS) of patients with thrombocytosis was significantly worse both in univariate (HR = 3.00, p = 0.03) and in multivariate analysis (HR = 4.68, p = 0.056) when adjusted for gender, age, tumor size and surgical margin. Thrombocytosis was also a good prognosticator of disease-free survival (DFS) with HR = 2.7, p = 0.018 and nearly significant in multivariate setting (HR = 2.26, p = 0.073). The platelet count is a valuable prognostic marker for the survival in patients with mCRC.

Kanavos P, Schurer W (2010) The dynamics of colorectal cancer management in 17 countries. Eur J Health Econ 10(Suppl 1):S115–S129CrossRefPubMed

McArdle CS, Hole DJ (2002) Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer 86:331–335PubMedCentralCrossRefPubMed

Riess L (1872) Zur pathologischen Anatomie des Blutes. Arch Anat Physiol Wissensch Med 39:237–249

Hernandez E, Lavine M, Dunton CJ, Gracely E, Parker J (1992) Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 69:2975–2977CrossRefPubMed

Pedersen LM, Milman N (1996) Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 9:1826–1830CrossRefPubMed

Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, Jakesz R (2003) Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 89:1098–1106PubMed

Wosnitzer M, Polland A, Hai Q, Hruby G, McKiernan J (2011) Role of preoperative platelet level in clinical and pathological outcomes after surgery for renal cortical malignancies. BJU Int 108:73–79CrossRefPubMed

Feng JF, Huang Y, Lu WS, Chen QX (2013) Preoperative platelet count in esophageal squamous cell carcinoma: is it a prognostic factor? Langenbecks Arch Surg 398(8):1115–22CrossRefPubMed

Heras P, Hatzopoulos A, Kritikos N, Kritikos K (2010) Platelet count and tumor progression in gastric cancer patients. Scand J Gastroenterol 45:1005–1006CrossRefPubMed

10.

Brown KM, Domin C, Aranha GV, Yong S, Shoup M (2005) Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 189:278–282CrossRefPubMed

11.

Buergy D, Wenz F, Groden C, Brockmann MA (2012) Tumor-platelet interaction in solid tumors. Int J Cancer 130:2747–2760CrossRefPubMed

12.

Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123–134CrossRefPubMed

13.

Nieswandt B, Hafner M, Echtenacher B, Mannel DN (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59:1295–1300PubMed

14.

Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185CrossRefPubMed

15.

Wang D, Huang HJ, Kazlauskas A, Cavenee WK (1999) Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 59:1464–1472PubMed

16.

Ho-Tin-Noe B, Goerge T, Wagner DD (2009) Platelets: guardians of tumor vasculature. Cancer Res 69:5623–5626CrossRefPubMed

17.

Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366:610–618PubMedCentralCrossRefPubMed

18.

Qiu MZ, Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH (2010) Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol 31:255–260CrossRefPubMed

19.

Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J (2012) Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 36:192–200CrossRefPubMed

20.

Lin MS, Huang JX, Zhu J, Shen HZ (2012) Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology 59:1687–1690PubMed

21.

Baranyai Z, Krzystanek M, Josa V, Dede K, Agoston E, Szasz AM, Sinko D, Szarvas V, Salamon F, Eklund AC, Szallasi Z, Jakab F (2014) The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer. Thromb Haemost 111:483–490CrossRefPubMed

22.

Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H (1999) Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med 245:295–300CrossRefPubMed

23.

Buss DH, Cashell AW, O’Connor ML, Richards F 2nd, Case LD (1994) Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 96:247–253CrossRefPubMed

24.

Schafer AI (2004) Thrombocytosis. N Engl J Med 350:1211–1219CrossRefPubMed

25.

Kulnigg-Dabsch S, Schmid W, Howaldt S, Stein J, Mickisch O, Waldhor T, Evstatiev R, Kamali H, Volf I, Gasche C (2013) Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis 19:1609–1616CrossRefPubMed

26.

Choi SI, Simone JV (1973) Platelet production in experimental iron deficiency anemia. Blood 42:219–228PubMed

27.

Choi SI, Simone JV, Jackson CW (1974) Megakaryocytopoiesis in experimental iron deficiency anemia. Blood 43:111–120PubMed

28.

Simanek R, Vormittag R, Ay C, Alguel G, Dunkler D, Schwarzinger I, Steger G, Jaeger U, Zielinski C, Pabinger I (2010) High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 8:114–120CrossRefPubMed

29.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907PubMedCentralCrossRefPubMed

30.

Evstatiev R, Bukaty A, Jimenez K, Kulnigg-Dabsch S, Surman L, Schmid W, Eferl R, Lippert K, Scheiber-Mojdehkar B, Michael Kvasnicka H, Khare V, Gasche C (2014) Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin. Am J Hematol 89:524–529PubMedCentralCrossRefPubMed

31.

Erpenbeck L, Schon MP (2010) Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 115:3427–3436PubMedCentralCrossRefPubMed

32.

33.

Ho-Tin-Noe B, Goerge T, Wagner DD (2009) Platelets: guardians of tumor vasculature. Cancer Res 69:5623–5626CrossRefPubMed

34.

Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT (2002) Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 62:2824–2833PubMed

35.

36.

De Vita F, Romano C, Orditura M, Galizia G, Martinelli E, Lieto E, Catalano G (2001) Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 21:45–52CrossRefPubMed

37.

Paule B, Belot J, Rudant C, Coulombel C, Abbou CC (2000) The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study. J Clin Pathol 53:388–390PubMedCentralCrossRefPubMed

38.

Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6:2702–2706PubMed

39.

Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA (1994) Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73:1882–1888CrossRefPubMed

40.

Takeuchi E, Ito M, Mori M, Yamaguchi T, Nakagawa M, Yokota S, Nishikawa H, Sakuma-Mochizuki J, Hayashi S, Ogura T (1996) Lung cancer producing interleukin-6. Intern Med 35:212–214CrossRefPubMed

41.

Corbeil J, Evans LA, Vasak E, Cooper DA, Penny R (1991) Culture and properties of cells derived from Kaposi sarcoma. J Immunol 146:2972–2976PubMed

42.

Chen Q, Solar G, Eaton DL, de Sauvage FJ (1998) IL-3 does not contribute to platelet production in c-Mpl-deficient mice. Stem Cells 16(Suppl 2):31–36CrossRefPubMed

43.

Gainsford T, Roberts AW, Kimura S, Metcalf D, Dranoff G, Mulligan RC, Begley CG, Robb L, Alexander WS (1998) Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production. Blood 91:2745–2752PubMed

44.

Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H (2001) Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 98:2720–2725CrossRefPubMed

45.

D’Hondt V, Humblet Y, Guillaume T, Baatout S, Chatelain C, Berliere M, Longueville J, Feyens AM, de Greve J, Van Oosterom A et al (1995) Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study. Blood 85:2347–2353PubMed

46.

van Gameren MM, Willemse PH, Mulder NH, Limburg PC, Groen HJ, Vellenga E, de Vries EG (1994) Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 84:1434–1441PubMed

47.

48.

Buss DH, Cashell AW, O’Connor ML, Richards F 2nd, Case LD (1994) Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 96:247–253CrossRefPubMed

49.

50.

Choi SI, Simone JV (1973) Platelet production in experimental iron deficiency anemia. Blood 42:219–228PubMed

51.

Choi SI, Simone JV, Jackson CW (1974) Megakaryocytopoiesis in experimental iron deficiency anemia. Blood 43:111–120PubMed

52.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081CrossRefPubMed

53.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRefPubMed

54.

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545CrossRefPubMed

55.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444CrossRefPubMed

56.

Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456–1462CrossRefPubMed

57.

Vakkila J, Lotze MT (2004) Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4:641–648CrossRefPubMed

58.

McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22:881–886CrossRefPubMed

59.

Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC (2006) An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 94:1568–1571PubMedCentralPubMed

60.

Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, Imrie CW (2005) Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 92:21–23PubMedCentralCrossRefPubMed

61.

Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ (2007) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110:1241–1247CrossRefPubMed

62.

Hilmy M, Campbell R, Bartlett JM, McNicol AM, Underwood MA, McMillan DC (2006) The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 95:1234–1238PubMedCentralCrossRefPubMed

63.

Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, Onitsuka T (2007) Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 27:3001–3004PubMed

Title: Thrombocytosis of Liver Metastasis from Colorectal Cancer as Predictive Factor
Authors: Valéria Jósa
Marcin Krzystanek
Tamás Vass
Tamás Lang
Viktória Juhász
Kamilla Szilágyi
Balázs Tihanyi
László Harsányi
Zoltán Szállási
Ferenc Salamon
Zsolt Baranyai
Publication date: 01-09-2015
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-015-9925-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Computer Aided Semi-Automated Evaluation of HER2 Immunodetection—A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy

Molecular and Clinicopathological Aspects of Prostate Cancer in Bulgarian Probands

Association and Prognostic Significance of the Functional −1562C/T Polymorphism in the Promoter Region of MMP-9 in Turkish Patients with Gastric Cancer

Identification of Target Genes Regulated by KSHV miRNAs in KSHV-Infected Lymphoma Cells

Single Nucleotide Polymorphisms (SNPs) of RAD51-G172T and XRCC2-41657C/T Homologous Recombination Repair Genes and the Risk of Triple- Negative Breast Cancer in Polish Women

Angiogenesis, Proliferative Activity and DNA Ploidy in Oral Verrucous Carcinoma: A Comparative Study Including Verrucous Hyperplasia and Squamous Cell Carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer